The 2026 AACR Report Highlights Advances and New Directions in Cancer Treatment has brought attention to the role of liquid biopsy in early-detection strategies. Liquid biopsy is moving beyond a niche alternative to tissue biopsy, with its commercial value lying in enabling molecular profiling, therapy selection, treatment monitoring, and detection of residual or recurring disease without requiring a conventional tissue sample in every case.
Introduction To Liquid Biopsy
Liquid biopsy analyzes biomarkers like circulating tumor DNA (ctDNA), RNA, and tumor-associated large extracellular vesicles (L-EVs) from blood, according to Towards Healthcare. The technology has been gaining traction, with the global liquid biopsy market projected to grow from USD 7.08 billion in 2025 to USD 27.42 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2035. The U.S. liquid biopsy market alone is projected to increase from USD 2.78 billion in 2026 to USD 8.90 billion by 2035, at a CAGR of 13.82%.
Applications And Potential
Liquid biopsy is increasingly used to monitor treatment response and detect residual or recurring disease after surgery, according to Towards Healthcare and OncoDaily. Clinicians are debating whether ctDNA results should guide adjuvant treatment decisions in colorectal, gastroesophageal, and pancreatic cancers, as discussed at the Northeast GI Oncology Congress 2026. New research is testing if liquid biopsies can detect breast cancer at Stage I by identifying rare cells and L-EVs, as seen in a clinical trial launched by researchers at USC Norris Comprehensive Cancer Center. L-EVs are tiny particles released by cancer cells that may be detectable at the earliest stages of disease onset.
Market Outlook And Future Directions
The market’s projected expansion reflects several overlapping demand pools: precision oncology, targeted cancer therapies, molecular monitoring, and the development of blood-based screening tests. These applications have different evidence requirements and commercial pathways, meaning companies need to assess them separately rather than treating all liquid biopsy products as interchangeable. Regulatory authorization, reimbursement, clinical utility, and relationships with pharmaceutical developers are important competitive factors for diagnostic businesses. A key strategic distinction exists between tests used to guide treatment in patients with known cancer and tests intended to screen apparently healthy populations.
Conclusion And Next Steps
Early findings suggest that liquid biopsy may provide a screening alternative for patients who face barriers to mammography or have undergone a mastectomy. The encouraging part is that liquid biopsy may offer an additional screening option for women who live in remote areas where access to screening services is limited. Patients should talk to their doctor about the potential benefits and limitations of liquid biopsy. As research continues to advance, it is essential to consult your doctor to understand how liquid biopsy can be used in cancer monitoring and early detection strategies.
Research And Development Challenges
According to Towards Healthcare, the global liquid biopsy market is projected to grow from USD 7.08 billion in 2025 to USD 27.42 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.5% from 2026 to 2035. However, this growth is contingent upon overcoming several research and development challenges.
One of the key challenges is the development of blood-based screening tests that can detect cancer at an early stage. As noted by Anastasia Martynova, MD, a breast cancer specialist and medical oncologist with USC Norris, “Our hope is to determine whether this test can provide more information about breast cancer screening and detection, particularly during the stages of the disease when it may be easier to treat.”
Additionally, the development of liquid biopsy tests that can detect rare cancer-associated cells and tumor-associated large extracellular vesicles (L-EVs) is crucial. As stated by Amanda M. Woodworth, MD, director of breast health at Keck Medicine, “If the test is shown to be effective, it could offer an additional screening option for women who face barriers to mammography, such as those who live in remote areas where access to screening services is limited.”
Integrating Liquid Biopsy Into Post-Surgical Monitoring
Beyond its utility in early detection, liquid biopsy is increasingly utilized after surgery to investigate whether molecular evidence of cancer remains. According to OncoDaily, ctDNA testing provides a mechanism to analyze blood samples for residual disease, which may help clinicians predict potential recurrence. This post-surgical application is a central topic of discussion among medical professionals, particularly regarding whether these molecular findings should actively guide adjuvant treatment decisions for patients with colorectal, gastroesophageal, and pancreatic cancers.
The clinical implementation of these tests involves complex decision-making processes. As highlighted at the Northeast GI Oncology Congress 2026, the primary challenge for clinicians is determining the appropriate intervention following a positive ctDNA result. Conversely, if a test returns a negative result, researchers are currently evaluating what level of evidence is required before a medical team might consider reducing a patient’s treatment regimen. The overarching goal is to determine if acting on the specific findings of a liquid biopsy can demonstrably improve patient outcomes.
This diagnostic approach represents a shift in how physicians manage patients following a known cancer diagnosis. While existing tests often focus on small fragments of DNA released by tumor cells, the integration of these biopsies into standard care pathways is intended to provide a more comprehensive view of a patient’s status. By monitoring for molecular signals in the blood, clinicians aim to better understand how cancer cells and their surrounding environment communicate, potentially allowing for more personalized and timely adjustments to therapeutic strategies.
Regulatory And Reimbursement Landscape
Regulatory authorization and reimbursement are critical competitive factors for diagnostic businesses in the liquid biopsy market, as noted by Towards Healthcare. The U.S. market outlook, projecting growth from USD 2.78 billion in 2026 to USD 8.90 billion by 2035 at a CAGR of 13.82%, underscores the importance of securing regulatory clearance and establishing sustainable reimbursement pathways. These factors directly influence adoption rates and commercial viability, particularly as companies navigate differing evidence requirements across precision oncology, targeted therapies, molecular monitoring, and blood-based screening applications.
The distinction between tests for guiding treatment in known cancer patients and those for screening healthy populations further shapes regulatory and reimbursement strategies. Therapy-selection assays tied to specific treatment decisions may follow companion diagnostic pathways, while screening tests require robust validation for population-level use. As the market expands, success will depend on aligning product development with evolving regulatory expectations and payer policies that reflect clinical utility and long-term value in cancer care pathways.
Sources
- Liquid Biopsy Market Research to Reach USD 27.42 Billion by 2035 as Cancer Blood Tests, AI Diagnostics and Precision Oncology Advance
- From Liquid Biopsy to New Treatment Modalities: What to Expect at Northeast GI Oncology Congress 2026 – OncoDaily
- Clinical trial to evaluate blood test for early detection of breast cancer
Photo: Welsh Government (OGL 3)
